Press On and Rising Tide Foundation for Clinical Cancer Research award Grant for $800,000 for a Pediatric Neuroblastoma Trial
June 5th, 2015 by Sarah Turner Davis
Atlanta, GA: The Press On Fund and the Rising Tide Foundation for Clinical Cancer Research (RTFCCR) are pleased to announce their first collaborative grant in the amount of $800,000 to Children’s Hospital of Los Angeles (CHLA), Children’s Healthcare of Atlanta (CHOA), and the University of Southern California, to initiate the New Approaches to Neuroblastoma Therapy (NANT) consortium’s Precision Clinical Trial.
The grant will allow Co-Principal Investigators Shahab Asgharadeh, M.D. of CHLA and Kelly Goldsmith, M.D. of CHOA to enrich bone marrow samples from children with relapsed neuroblastoma for the purpose of identifying specific genomic alterations leading to tumor progression and therapy resistance.
The primary aim of the study is to identify potentially targetable genetic and immunologic biomarkers in relapsed neuroblastoma.
The study will also assess a novel method for enriching tumor cells from bone marrow aspirates to support gene sequencing, which could potentially allow a much larger group of relapsed neuroblastoma patients to access future personalized medicine trials. A corroboration of this methodology could lead to a wider application in other adult or pediatric solid tumors.
Neuroblastoma is the most common solid tumor of the central nervous system in children. High-risk neuroblastoma is highly lethal and is responsible for 15% of childhood cancer related deaths. The five-year survival rate for high risk neuroblastoma stands at only 30% and recurrent neuroblastoma almost always fatal.
This grant was made possible by a strategic collaboration between Press On and the Rising Tide Foundation for Clinical Cancer Research in Switzerland. RTFCCR is dedicated to empowering and supporting pioneering scientists and clinical investigators to make critical headway in cancer research. With the cooperation of the CSRA Community Foundation, Press On Strives to leverage its research dollars with other cancer research oriented foundations and non-profits, like Rising Tide, and as evidenced in its Genomic Research Study with St Jude and Wash U, and its
The Rising Tide Foundation for Clinical Cancer Research is an entrepreneurial, private non-profit organization established in Switzerland in 2010. It is committed to empowering and collaborating with global research excellence centers and scientists to advance novel strategies and treatments to help cancer patients improve their quality of life and win the fight against cancer. RTFCCR is funding translational and clinical cancer research with the highest potential for near-term patient impact. Press On is a field of interest fund administered by the Community Foundation of the CSRA, which is located in Augusta, GA. Press On was founded by Atlanta residents Stephen and Erin Chance after their son, Patrick, was diagnosed with high risk neuroblastoma. The Chances joined forces with Tara and Turner Simkins of Augusta when their son, Brennan, was diagnosed with acute myeloid leukemia, an extremely deadly form of childhood cancer. Patrick died on his ninth birthday after fighting for almost six years. Brennan is alive and doing well after a groundbreaking treatment regimen including four bone marrow transplants.
The NANT consortium brings together a multidisciplinary team of laboratory and clinical scientists from 14 pediatric hospitals and institutions in the US and Canada with complementary expertise in genetics, biology, immunology, chemistry, pathology, biostatistics, clinical investigations, and imaging all with a single focus on finding better treatments for children with high-risk neuroblastoma.